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SHORT COMMUNICATION
Deficiency of Kruppel-like factor KLF4 in myeloid-derived
suppressor cells inhibits tumor pulmonary metastasis in mice
accompanied by decreased fibrocytes
Y Shi1,2, L Ou2,3, S Han4, M Li5, MMO Pena6, EA Pena7, C Liu8, M Nagarkatti2, D Fan9 and W Ai2
The importance of immunosuppressive myeloid-derived suppressor cells (MDSCs) bearing monocyte markers in tumor metastasis
has been well established. Recently, it was reported that these cells possess phenotypic plasticity and differentiate into fibrocytes,
very distinct cells that are precursors of tumorigenic myofibroblasts. However, the importance of this transdifferentiation in
tumor metastasis has not been explored. Here, we describe the role of MDSC-derived fibrocytes in tumor metastasis that is regulated
by Kruppel-like factor 4 (KLF4), a transcription factor that is critical to monocyte differentiation and to promotion of cancer
development. Using mouse metastasis models of melanoma and breast cancer, we found that KLF4 knockout was associated with
significantly reduced pulmonary metastasis, which was accompanied by decreased populations of MDSCs, fibrocytes and
myofibroblasts in the lung. Cause-effect studies by adoptive transfer revealed that KLF4 deficiency in MDSCs led to significantly
reduced lung metastasis that was associated with fewer MDSC-derived fibrocytes and myofibroblasts. Mechanistically, KLF4
deficiency significantly compromised the generation of fibrocytes from MDSCs in vitro. During this process, KLF4 expression levels
were tightly linked with those of fibroblast-specific protein-1 (FSP-1), deficiency of which resulted in no metastasis in mice as has
been previously reported. In addition, KLF4 bound directly to the FSP-1 promoter as determined by chromatin immunoprecipitation
and overexpression of KLF4 increased the FSP-1 promoter activities. Taken together, our results suggest that MDSCs not only execute
their immunosuppressive function to promote metastatic seeding as reported before, but also boost metastatic tumor growth after
they adopt a fibrocyte fate. Therefore, KLF4-mediated fibrocyte generation from MDSCs may represent a novel mechanism of MDSCs
contributing to tumor metastasis and supports the feasibility of inhibiting KLF4 or FSP-1 to prevent tumor metastasis.
Oncogenesis (2014) 3, e129; doi:10.1038/oncsis.2014.44; published online 24 November 2014
INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) are a bone marrow-
originated heterogeneous population of immature myeloid cells
with phenotypic plasticity1 and involved in multiple inflammatory
conditions.2,3 They are broadly defined as CD11b+Gr-1+ or
CD11b+Ly6G+ cells in mice, with a wider range of markers in
humans. Increased MDSCs are associated with tumor growth and
metastasis in both tumor-bearing mice and cancer patients,4
which makes this population a novel therapeutic target.5 Recently,
MDSCs were found to be differentiated into fibrocytes,6 a
very distinct cell type that may promote tumorigenesis by
incorporating into the tumor stromal and differentiating into
myofibroblasts.7,8 In addition, expansion of fibrocytes has
been observed in the microenvironment of solid tumors9 and
circulation of subjects with metastatic cancer,10 which facilitate
tumor metastasis.11 However, the importance and the underlying
molecular mechanism of MDSCs transdifferentiation into
fibrocytes in tumor metastasis have not been clearly elucidated.
Kruppel-like factor 4 (KLF4) is a transcription factor12 critical to
monocyte differentiation,13 and has an oncogenic function in
cancer development.14,15 Recently, we found that KLF4 deficiency
in mammary tumor cells compromised the recruitment and
function of MDSCs in primary and metastatic tumors, resulting in
attenuated tumor development.16 However, whether and how
KLF4 in MDSCs, a major component of immunosuppressive cells in
tumor microenvironment,17 regulates tumor metastasis has not
been reported before.
In this study, we found that KLF4 deficiency in mice led to
reduced pulmonary metastasis, which was accompanied by
decreased populations of a subset of MDSCs bearing features of
CCR2+CD11b+Ly6Gint (CCR2+ MDSCs) and reduced numbers of
fibrocytes and myofibroblasts in the lung. Cause-effect studies
indicated that KLF4 deficiency in CCR2+ MDSCs was responsible for
compromised lung metastasis. Mechanistically, KLF4 regulated the
fibrocyte generation from CCR2+ MDSCs in vitro and occupied the
fibroblast-specific protein-1 (FSP-1) promoter, which may contribute
to increased promoter activities. Taken together, our study
demonstrates a critical role of KLF4-mediated fibrocyte generation
from CCR2+MDSCs in tumor metastasis, which may provide a
therapeutic strategy to treat metastasis by targeting KLF4 or FSP-1.
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RESULTS AND DISCUSSION
KLF4 deficiency in mouse bone marrow drastically reduced lung
metastasis that was accompanied by decreased recruitment of
CCR2+ MDSCs in the lung
We recently reported that mammary tumor cell-expressing KLF4
facilitated primary tumor growth and pulmonary metastasis.16 The
accumulation of MDSCs in bone marrow, spleen and primary
tumors were all decreased in mice that were inoculated with breast
cancer cells lacking KLF4 expression. However, KLF4 deficiency is
restricted to tumor cells in this study, and the effect of KLF4 in
MDSCs on tumor metastasis still remains unknown. Therefore, we
generated inducible KLF4-knockout mice (Rosa26CreER/KLF4
(flox+/+) mice on C57BL/6 background) and spontaneous KLF4-
knockout mice (FSP-1-Cre/KLF4 (flox+/+) mice on BalB/c back-
ground). The efficiency of KLF4 knockout in both models was
confirmed by quantitative reverse transcriptase–PCR indicating
that KLF4 expression in bone marrow was decreased to o10% of
that in the wild-type mice (data not shown). We then established
metastatic mouse models using B16F10-Luc2 melanoma and 4T1-
Luc2 breast cancer cells in these mice. Ten days after intravenous
tumor cell inoculation, in vivo bioluminescent imaging showed that
the signals of lung metastasis in KLF4-knockout (KLF4− /−) groups
were much lower than those in the control (KLF4+/+) groups in
both models (Supplementary Figure S1A). Two weeks after tumor
inoculation, mice were sacrificed and a significantly decreased
incidence of lung metastasis was found in the KLF4− /− groups
(Supplementary Figure S1B). Flow cytometric analysis showed that
the percentage of MDSCs in bone marrow of the KLF4− /− group
was almost the same as the KLF4+/+ group in both of the two
metastatic models. In addition, although MDSCs were reduced in
spleen and lung after KLF4 was knocked out in these two models,
the differences between the KLF4− /− and KLF4+/+ groups were not
statistically significant (data not shown).
Note that KLF4 deficiency was systemic in the above mentioned
mouse models. To exclusively investigate whether the KLF4-
knockout effect on tumor metastasis was contributed by bone
marrow KLF4, we performed the same experiments in the B16F10-
Luc2 melanoma metastatic model using chimeric mice that had
received bone marrow cells from B6 Rosa26CreER/KLF4(lox+/+)/β-
actin-EGFP+ donor mice. Similar with the systemic KLF4-knockout
mice, average bioluminescence intensity was decreased from 9.31
(±1.92) × 103 photons/s in the lung of control mice to 2.86
(±1.34) × 103 photons/second in the lung of mice with bone
marrow KLF4 knockout induced by TAM (Figure 1a, Po0.05).
Consistently, drastically decreased numbers of pulmonary meta-
static nodules were found in the KLF4− /− group when compared
with the KLF4+/+ group (Figure 1b) and metastatic area was also
reduced upon KLF4 deficiency in bone marrow (Figure 1c).
Similarly, there were still no significant changes of MDSCs in bone
marrow, spleen and lung after KLF4 knockout in the bone marrow
(data not shown), even though the percentages of MDSCs in the
lung were markedly reduced (Supplementary Figure S2A, P=0.165).
MDSCs are heterogeneous. It was recently reported that a
subset of MDSCs characterized by CD11b+Gr-1+CD115+ was
preferentially recruited to the lung through the CCL2/CCR2
signaling pathway, resulting in facilitation of pulmonary metas-
tasis of mammary tumor.18 We therefore postulated that KLF4 may
only regulate a specific subpopulation of MDSCs, such as CCR2+
MDSCs, leading to compromised lung metastasis in our studies.
Indeed, in the B16F10 chimeric metastasis model, the CCR2+
MDSC subset decreased from 2.41 (±0.21)% to 0.86 (±0.25)% in
lung (Figure 1d, Po0.05), but not in spleen (Supplementary
Figure S2B, P= 0.057) or bone marrow (data not shown).
Consistent with these results in the B16F10 model, CCR2+ MDSCs
in lung (Supplementary Figure S3A, Po 0.001), but not in spleen
or bone marrow (data not shown), were also significantly reduced
in the 4T1 metastatic model. Collectively, these data suggested
that KLF4 in bone marrow regulated the pulmonary recruitment of
CCR2+ MDSCs, and decreased CCR2+ MDSCs reduced tumor lung
metastasis.
KLF4 deficiency in bone marrow was associated with significantly
decreased numbers of fibrocytes and myofibroblasts in metastatic
lung
MDSCs are well known for their immunosuppressive functions
under different pathological conditions including cancer
development.19 As discussed above, KLF4 knockout had limited
effects on the recruitment of the whole population of MDSCs, but
significantly reduced the numbers of CCR2+ MDSC subset in lung.
It suggested that the significantly reduced lung metastasis after
bone marrow KLF4 knockout was contributed by other factors
beyond the immunosuppressive function of CCR2+ MDSCs.
Recently it was reported that MDSCs had a high potential to
differentiate into fibrocytes.6 As mesenchymal cells that arise from
monocyte precursors, fibrocytes have both the inflammatory
features of macrophages and the tissue remodeling properties of
fibroblasts.20 Circulating fibrocytes can traffic to lungs and
differentiate into fibroblasts,21 the precursors of myofibroblast
that are crucial tumor stromal component.22 Therefore, there was
an intriguing possibility that the CCR2+ MDSCs exerted their ability
of promoting metastatic tumor growth mostly by adopting a
fibrocyte fate after they were recruited to lung. To test this, we first
used B16F10 chimeric metastasis model. As the chimeric mice
received EGFP-expressing bone marrow cells, we used COL1A1+
CD45+CD11b+EGFP+ and CD11b+α-SMA+EGFP+ to identify bone
marrow-derived fibrocytes and myofibroblasts, respectively. The
peripheral blood monocytes and lung single cells of the chimeric
mice were examined by flow cytometry. As shown in Figure 2a, the
percentage of fibrocytes in peripheral blood monocytes dropped
from 2.50 (±0.32) % in the KLF4+/+ group to 0.63 (± 0.40) % in the
KLF4− /−group (Figure 2a, Po0.05). Although the percentage of
fibrocytes and myofibroblasts in the lung was similar between the
two groups (KLF4+/+ 2.54( ±0.28) % vs KLF4− /− 1.67(± 0.29) % for
fibrocytes, P= 0.10, KLF4+/+ 17.03( ±1.15) % vs KLF4− /− 16.22(±
0.52) % for myofibroblasts, P=0.60), the total cell number of
COL1A1+CD45+CD11b+ EGFP+ and CD11b+α-SMA+EGFP+ cells in
the KLF4− /−group decreased by 64.30 and 64.34%, respectively
(Figure 2b). In parallel with these observations, the immunofluor-
escent staining of lung sections showed that the numbers of
COL1A1+EGFP+ and α-SMA+EGFP+ double positive cells were
significantly reduced in the KLF4− /− group when compared to
those in the KLF4+/+ group (Figures 2c and d). Consistently, in the
4T1 metastatic model, decreased populations of fibrocytes
(COL1A1+CD45+CD11b+) were also observed in peripheral blood
monocytes and lung (Supplementary Figure S3B and S3C,
Po0.001 and Po0.01). Together, these findings supported our
hypothesis that CCR2+ MDSCs are not only preferentially recruited
to target organs to prepare for metastatic seeding, but also boost
metastatic tumor growth by adopting a fibrocyte fate. In addition,
KLF4 regulates both of these two progresses.
KLF4 ablation in CCR2+ MDSCs reduced pulmonary metastasis that
was associated with decreased numbers of fibrocytes
To exclude the effect of KLF4-mediated development of MDSCs
and to test the direct effect of KLF4-regulated fibrocyte generation
from CCR2+ MDSCs on tumor metastasis, a cause-effect study was
performed. We sorted this specific MDSC subset from the lungs of
B6 Rosa26CreER/KLF4 (flox+/+)/β-actin-EGFP+ mice bearing B16F10
melanoma, mixed with B16F10 tumor cells, and then injected
wild-type mice with the mixture intravenously, followed by
tamoxifen (TAM) injection to induce KLF4 knockout (Figure 3a).
In the control group, mice only received B16F10 tumor cells, but
still intraperitoneally injected with TAM or sunflower seed oil as
the control. At day 7 after tumor cell inoculation, mice were
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sacrificed. The gross view and hematoxylin and eosin staining of
the lung in the control group showed that there was no difference
in the incidence of lung metastasis between the mice admini-
strated with TAM or sunflower seed oil (data not shown). However,
the pulmonary metastatic nodules in the KLF4− /− and control
groups were drastically fewer than those in the KLF4+/+ group. The
percentages of lung metastatic areas in KLF4− /− (2.64 ( ± 0.16)%)
and control group (2.87 ( ± 0.21)%) were also significantly lower
than those in the KLF4+/+ group (11.71 ( ± 0.88)%; Figure 3b). Note
that KLF4 deficiency in CCR2+ MDSCs led to similar metastatic
areas in KLF4− /− group as in the control group. The results
demonstrated that CCR2+ MDSCs did facilitate the seeding and
growth of pulmonary metastatic nodules in a KLF4-dependent
manner. Because the transplanted CCR2+ MDSC cells also carried
the EGFP marker, we examined their differentiation in the lung by
immunofluorescent staining of lung cryosections with COL1A1
Figure 1. KLF4 deficiency in mouse bone marrow drastically reduced lung metastasis that was accompanied by decreased recruitment of CCR2+
MDSCs in the lung. (a) Six-week old C57BL/6 (B6) wild-type mice (The Jackson Laboratory, Bar Harbor, ME, USA) were lethally irradiated (900 rad)
and then transplanted with bone marrow cells (1.0 × 106 cells per recipient mouse) from B6 Rosa26CreER/KLF4 (flox+/+)/β-actin-EGFP mice, which
were generated by crossing tamoxifen-inducible RosaCreER mice (01XAB, NCI) with KLF4 (flox) mice (029877-Mu, MMRRC) and β-actin-EGFP mice
(The Jackson Laboratory). Four weeks later, KLF4 knockout of chimeric mice was induced by daily intraperitoneal injection of tamoxifen (TAM,
Sigma-Aldrich, St Louis, MO, USA; 50mg/kg) for five consecutive days, followed by intravenous injection of B16F10-Luc2 tumor cells (Caliper Life
Sciences, Middlesex, MA, USA). Sunflower seed oil (Sigma-Aldrich) was used as control. These mice were then monitored by IVIS Spectrum
Fluorescence and Bioluminescence Imaging System (Caliper Life sciences) to detect the signals of pulmonary metastasis. Results of
representative control (KLF4+/+) and TAM-induced (KLF4− /−) mice at day 10 after tumor cell inoculation were shown (n=8, Po0.05). (b)
Representatives of lung macrometastases from the chimeric mice as described in a were shown. (c) Left, representative HE stained lung sections
with red arrows pointing the metastatic lesions were displayed (scale bars= 100 μm). Right, percentages of metastatic areas in control and TAM-
induced chimeric mice were quantified. (d) Lungs were minced into small fragments (o1mm3) and digested in 10 ml of dissociation solution
(RPMI 1640 medium supplemented with Collagenase type I (200 U/ml) and DNase I (100 μg/ml)) for 60min at 37 °C. Lung-infiltrating immune
cells were further purified using Percoll (Sigma-Aldrich) according to the manufacturer’s instructions. The cells with intermediate Ly6G (clone
RB6-8C5, eBiosciences, San Diego, CA, USA) signals (Ly6GInt) were gated (left) followed by further flow cytometry analysis (right) using CD11b
(clone M1/70, eBiosciences) and CCR2 (R&D, Minneapolis, MN, USA) antibodies. The flow cytometry were performed and data were analyzed
using FACSAria II (BD Biosciences, San Jose, CA, USA). Representative dot plots in each group were shown (n= 8). Mean± s.e.m., ***Po 0.001.
KLF4 regulates fibrocyte generation from MDSCs
Y Shi et al
3
© 2014 Macmillan Publishers Limited Oncogenesis (2014), 1 – 7
and α-SMA antibodies. The results showed that although there was
no difference in the total number of EGFP+ cells between the
KLF4+/+ and KLF4− /− group (data not shown), COL1A1+EGFP+ cells
decreased from 6.20 ( ±0.66)% in the KLF4+/+ mice to 1.6 (±0.51)%
in KLF4 deficient mice (Figure 3c, Po0.001). Similarly, α-SMA+EGFP+
cells also decreased in KLF4− /− mice (KLF4+/+ 4.6 (±0.68)% versus
KLF4− /− 1.4 (±0.40)%, Po0.01, Figure 3c), which further supported
our speculation that KLF4 regulates the differentiation of CCR2+
MDSCs after they are recruited to the lung in vivo.
KLF4 gene expression was tightly linked with that of FSP-1 in
fibrocyte generation from MDSCs
To elucidate the underlying molecular mechanism, we proceeded to
examine the role of KLF4 in fibrocyte generation from MDSCs in vitro.
Figure 2. LF4 deficiency in bone marrow was associated with significantly decreased numbers of fibrocytes and myofibroblasts in meta-
static lung. (a) The peripheral blood monocytes (PBMCs) from the chimeric mice as described in Figure 1 were isolated using Histoplaque
(Sigma-Aldrich) according to the manufacturer’s instructions. EGFP-expressing PBMCs were stained and gated by biotin-conjugated mouse
Collagen Type I alpha1 antibody (COL1A1; Rockland, Gilbertsville, PA, USA; left) and further analyzed using CD45 (clone 30-F11, eBiosciences)
and CD11b antibodies (right) by flow cytometry. Representative dot plots were shown (n= 8, Po0.05). (b) Lung-infiltrating immune cells were
stained with biotin-conjugated mouse COL1A1, rabbit anti-mouse α-SMA (Millipore, Billerica, MA, USA), CD11b and CD45 antibodies and then
examined using flow cytometry. Quantifications of the total number of COL1A1+CD45+CD11b+EGFP+ cells (left) and CD11b+α-SMA+EGFP+
cells (right) in lung were shown based on cell counting and flow cytometry data. (c and d) Representative immunofluorescence staining of
lung tissues with rabbit anti-mouse COL1A1 (Rockland; 1:200, scale bars= 100 μm) and α-SMA (1:200, scale bars= 50 μm). COL1A1+EGFP+ and
α-SMA+EGFP+ double positive cells (yellow arrows) within dotted lines encircling metastatic lesions were counted for every five high power
fields (HPF) and compared. Mean± s.e.m., *Po0.05, **Po0.01, ***Po0.001.
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Splenocytes from Rosa26CreER/KLF4 (flox+/+) mice were purified
followed by fibrocyte generation assay with recombinant murine
interleukin-13 and macrophage colony-stimulating factor as
previously described.23 4-OH TAM was used to induce KLF4
knockout. Three days after the cytokine treatment, the cells were
stained and the numbers of fibrocytes per 1×105 splenocytes in
each group were counted. While there were 58±7 fibrocytes per
1×105 splenocytes in the control group, the number of fibrocytes
decreased to 5±2 fibrocytes per 1×105 splenocytes in the presence
of 5 μM 4-OH TAM (Figure 4a). In the presence of 10 μM of 4-OH, there
were no fibrocytes generated from splenocytes (data not shown).
Quantitative reverse transcriptase–PCR analysis revealed that expres-
sion levels of KLF4 and FSP-1 were significantly elevated after the
application of interleukin-13 and macrophage colony-stimulating
factor, and KLF4 knockout induced by 4-OH TAM correlated with
significant downregulation of FSP-1 expression (Figure 4b). Consis-
tently, the expression levels of FSP-1 in bone marrow, spleen and
lung of the chimeric metastatic model were all decreased upon KLF4
knockout (Supplementary Figure 4), accompanied with deceased
lung metastasis. FSP-1 is a member of S100 superfamily of calcium-
binding proteins whose expression level is strongly associated with
an aggressive metastatic phenotype and worse prognosis for
patients with various malignancies.24 The causative role of FSP-1 in
tumor metastasis has been well established in literature.24,25 Given
the fact that FSP-1 has a specific expression in fibroblasts and is also
found in more than 90% of monocytes of the host immune system,26
it is quite possible that there is a lineage link between the two very
different cell types. Our in vivo data has shown that the populations
Figure 3. KLF4 ablation in CCR2+ MDSCs reduced pulmonary metastasis that was associated with decreased numbers of fibrocytes.
(a) Rosa26CreER/KLF4 (flox+/+)/β-actin-EGFP mice were inoculated under the dorsal skin with 5 × 105 B16F10-Luc2 cells. Three to four weeks
later, CCR2+ MDSCs were sorted from the lung of the tumor-bearing mice, mixed with B16F10 melanoma cells and injected into WT mice
intravenously, followed by induction of KLF4 knockout as described in Figure 1. The mice in the control group were injected with B16F10
melanoma cells only, but were still treated with tamoxifen or sunflower seed oil. Mice were sacrificed 1 week later for various analyses. (b) Left,
representative lung macrometastases (top) and hematoxylin and eosin stained sections with red arrows pointing metastatic lesions (bottom)
from the mice as described in a were shown (scale bars= 100 μm). Quantification of percentages of metastatic areas in each group was
showed on the right. (c) and (d) Representative IF staining of lung tissues with COL1A1 (1:200) and α-SMA (1:200). COL1A1+EGFP+ and α-
SMA+EGFP+ double positive cells (yellow arrows) within dotted lines circling metastatic lesions were counted for every five HPF and compared
(scale bars= 50 μm). Mean± s.e.m., **Po 0.01, ***Po 0.001. HPF, high power fields; IF, immunofluorescent; NS, not significant; WT, wild type.
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of CCR2+MDSCs, fibrocytes and myofibroblasts were highly corre-
lated, suggesting that fibrocytes are the key to connect the host
immune cells with fibroblasts in the tumor microenvironment by
carrying the expression/function of FSP-1.
To further test our hypothesis, we sorted four different subsets
of MDSCs from murine splenocytes based on CD11b and Ly6G
signals (Figure 4c) and performed quantitative PCR analysis and
fibrocyte generation assay. In agreement with our speculation, the
Figure 4. KLF4 gene expression was tightly linked with that of FSP-1 in fibrocyte generation from MDSCs. (a) Splenocytes from Rosa26CreER/
KLF4 (flox+/+) mice were purified and subjected to fibrocyte generation using a recently developed approach with the application of murine
interleukin (IL)-13 (50 ng/ml) and macrophage colony-stimulating factor (25 ng/ml).23 4-OH tamoxifen (4-OH TAM, Sigma-Aldrich) was used to
induce KLF4 knockout in vitro and 100% ethanol as a control. Three days later, the cells were stained with Hema 3 staining kit (Fisher Scientific,
Waltham, MA, USA) and the numbers of fibrocytes per 1 × 105 splenocytes in each group were counted. Left, representative photographs of
fibrocytes generated from splenocytes (red arrows) were shown. Right, the number of fibrocytes per 1 × 105 splenocytes in each group was
counted and compared (n= 5). (b) The total RNA of fibrocytes generated as described in a were extracted using Trizol Reagent (Invitrogen,
Grand Island, NY, USA) according to the manufacturer’s instructions. First-strand cDNA synthesis and quantitative reverse transcriptase–PCR
(qRT–PCR) were performed as described previously.15 The relative expression levels of KLF4 and FSP-1 were normalized to that of GAPDH.
Primer sequences for qRT–PCR were listed in Supplementary Table S1. (c) Four different MDSC subsets in mouse splenocytes were gated using
CD11b and Ly6G antibodies (left) and then sorted for qRT–PCR (middle) and fibrocyte generation assays (right). (d) Left, KLF4 bound to the
promoter region of FSP-1 by the chromatin immunoprecipitation assay as we previously described28 using NIH 3T3 cells (ATCC, Manassas, VA,
USA). Two KLF4 antibodies (KLF4-1 antibody from our laboratory29 and KLF4-2 antibody from Genespin (Milano, Italy)) were used to
precipitate DNA–protein complexes followed by PCR to amplify a 135-bp fragment in the FSP-1 promoter. Normal rabbit immunoglobulin G
(IgG, Santa Cruz Biotechnology, Dallas, TX, USA) was used as a negative control. The PCR primers were listed in Supplementary Table 1. Right,
KLF4 overexpression increased the promoter activities of FSP-1 by transient transfection and dual luciferase assay. A ~ 2.3 kb mouse FSP-1
promoter region was amplified (MGI: 1330282, nucleotide position − 1104 to 1224) using the primers listed in Supplementary Table 1. It was
cloned into pGL2 basic vector (Promega, Sunnyvale, CA, USA) and confirmed by sequencing. FSP-1 promoter luciferase reporter and KLF4-
overexpressing construct were co-transfected into NIH 3T3 cells using TurboFect (Thermo Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions. The empty pGL2 vector was used as a control. Two days after transfection, the cells were lysed and the effect of
KLF4 overexpression on FSP-1 promoter activity was assessed using the dual luciferase assay system (Promega). Mean± s.e.m., *Po 0.05,
**Po 0.01.
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highest expression levels of KLF4, FSP-1 and CCR2 coexisted in
CD11b+Ly6Gint MDSCs (namely CCR2+MDSCs, P2 in Figure 4c)
among all the MDSC subsets, and this subpopulation showed the
most efficient fibrocyte generation as well (Figure 4c). To examine
the potential regulation of FSP-1 transcription by KLF4, we first
performed chromatin immunoprecipitation assay using two
different KLF4 antibodies to examine the direct binding of KLF4
with the FSP-1 promoter. As shown in the left panel of Figure 4d,
both KLF4 antibodies but not control immunoglobulin G pulled
down a fragment in the FSP-1 promoter region as amplified by
PCR. We also generated a ~ 2.3 kb FSP-1 promoter luciferase
reporter construct and performed dual luciferase assays. As shown
in the right panel of Figure 4d, overexpression of KLF4 tripled the
FSP-1 promoter activity when compared with that of the vector
control. Together, these data suggest a direct regulation of FSP-1
expression by KLF4 at the transcription level in the process of
fibrocyte generation from CCR2+ MDSCs.
Collectively, our data suggest that KLF4 in bone marrow
promotes tumor metastasis by regulating the recruitment of
CCR2+ MDSCs, likely in a CCL2/CCR2-dependent manner because
KLF4 regulates CCR2 expression.27 In addition, once CCR2+ MDSCs
are recruited to the lung, KLF4 further regulates their differentiation
into fibrocytes resulting in increased metastatic tumor growth
probably dependent on KLF4-mediated FSP-1 expression. This
finding uncovered, to our knowledge, a novel mechanism whereby
FSP-1 promotes tumor metastasis by fibrocyte generation from
MDSCs. One limitation of our study is that we only used KLF4
deficient mouse models. Future experiments with transgenic mice
overexpressing KLF4 in bone marrow will further confirm our
observations. In addition, to confirm our hypothesis that KLF4
promotes tumor metastasis in a FSP-1 dependent manner, future
experiments will be performed to test whether ectopic expression
of KLF4 can rescue FSP-1 knockout-induced phenotypes of tumor
metastasis. However, in Fsp-1-Cre/KLF4 (flox+/+) mice, KLF4
deficiency was correlated with drastic downregulation of FSP-1
(data not shown). These results not only confirmed regulation of
FSP-1 by KLF4, but also supported our overall hypothesis. Finally,
further studies are needed to fully characterize the mechanism
whereby KLF4 regulates FSP-1 transcription.
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